Pacira Pharmaceuticals Stock News

-- EXPAREL average daily sales for January 2022 were 104% of January 2021 -- -- EXPAREL average daily sales for January 2022 were 104% of January 2021 --

InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto

A Relative Strength Rating upgrade for Pacira Pharmaceuticals shows improving technical performance. Will it continue?

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Community Health's (CYH) wholly-owned arm exhibits monetary discretion by pricing senior notes to procure funds.

Pacira BioSciences, D.R. Horton ArcBest, Axis Capital Holdings and CF Industries are highlighted in this Analyst Blog Article.

PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.

PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.

Banking on its strategic measures and a streamlined business, Mednax (MD) holds potential to reap benefits for investors.

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

Community Health Systems (CYH) is focused on making strategic acquisitions to boost its business through inorganic growth.

Centene (CNC) is well poised for growth on the back of improving revenues, continuous expansion plans for the MA business and sufficient cash-generating abilities.

Amgen (AMGN) signs a collaboration agreement with Generate Biomedicines to develop protein therapeutics across several therapeutic areas and multiple modalities.

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.